18+ · Research use only
Retatrutide vs semaglutide: the cost-per-result math.
Semaglutide built the incretin market. Retatrutide's Phase 2 numbers reached past it. What the published data says, and what each route costs in the Philippines.
What the trials published
Semaglutide is a single-target GLP-1 receptor agonist, the compound behind Ozempic and Wegovy. Its landmark result was STEP 1 (NEJM 2021): 14.9% mean weight reduction at 68 weeks. That figure redefined what the field expected from a metabolic compound and created the market every later incretin now competes in.
Retatrutide targets three receptors, GIP, GLP-1 and glucagon, and its Phase 2 trial (Jastreboff et al., NEJM 2023) reported 24.2% mean reduction at 48 weeks, and Phase 3 TRIUMPH-1 reported 28.3% at 80 weeks. Shorter trial, larger number. The trials are not directly comparable, different populations and durations, but the direction is hard to argue with: the highest retatrutide dose groups passed semaglutide's 68-week figure in roughly half the time. Phase 3 TRIUMPH results are still accumulating through 2026, so retatrutide remains an investigational compound with no approved product anywhere.
Two price categories, not two prices
The cost comparison is really a comparison of categories. Pharmacy semaglutide in the Philippines is a prescription pharmaceutical: branded pens dispensed through pharmacies, priced accordingly, with a monthly cost that runs well into five figures in pesos for ongoing use. That price buys an approved product, a fixed-dose delivery device and the pharmacy channel behind it.
Retatrutide has no pharmacy product to buy at any price. It exists only as an investigational compound, and from local Philippine stock a 20mg lyophilized vial is ₱3,775, or ₱3,390 with 10% off. That is a four-figure vial against a five-figure monthly pharmacy spend, but the two numbers buy different things: raw compound with batch-numbered labels and Metro Manila cold storage on one side, a finished regulated medicine on the other. Anyone weighing the two should be clear-eyed about that difference, which is covered in more depth in the RUO vials versus pharmacy pens comparison.
How the research market reads it
For research buyers, the choice is mostly settled by what question the work is asking. Semaglutide is the reference compound: the deepest human dataset, an approved product, years of post-market literature. Retatrutide is the frontier: the strongest reported Phase 2 curve in the class and an active Phase 3 program whose readouts the whole field is watching. Locally, that translates into retatrutide being the most requested compound in the Primara Labs catalogue, with same-day Metro Manila dispatch for orders verified before noon and courier reaching Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5. Current stock and batch details are on the product page, and the wider incretin picture is mapped in the 2026 GLP-1 landscape.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
Retatrutide vs semaglutide questions
How do retatrutide and semaglutide compare on published results?
Retatrutide reported 28.3% mean weight reduction at 80 weeks in Phase 3 TRIUMPH-1, after 24.2% at 48 weeks in Phase 2 (Jastreboff et al., NEJM 2023). Semaglutide reported 14.9% at 68 weeks in STEP 1 (NEJM 2021). Different trials and designs, but the gap between the two headline figures is large.
How much does retatrutide cost in the Philippines?
Retatrutide 20mg is ₱3,775 at Primara Labs, or ₱3,390 with the 10% discount, from local Metro Manila stock with same-day dispatch for orders verified before noon.
Can I buy semaglutide as a vial from Primara Labs?
Yes. Semaglutide 15mg is in the catalogue at ₱2,210, or ₱1,990 with the standing 10% off. That is a lyophilized vial sold for research use only, not the prescription pen sold through pharmacies, which remains a separate product and market.
Why is semaglutide so much more expensive per month?
Pharmacy semaglutide is a finished, approved pharmaceutical: branded pens, pharmacy margins, and prescription-channel distribution all sit in the price. A vial sold for research use is raw lyophilized compound with none of that overhead, which is why the two price categories are so far apart.